Terilyn Monroe Sells 10,031 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 10,031 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $112.08, for a total transaction of $1,124,274.48. Following the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at $2,352,559.20. The trade was a 32.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Guardant Health Stock Up 1.3%

Shares of Guardant Health stock opened at $110.17 on Friday. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of -34.32 and a beta of 1.58. Guardant Health, Inc. has a twelve month low of $34.80 and a twelve month high of $113.91. The company’s fifty day moving average is $102.14 and its 200 day moving average is $73.32.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same period last year, the company earned ($0.88) EPS. The business’s revenue was up 38.5% on a year-over-year basis. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

GH has been the subject of a number of recent analyst reports. Canaccord Genuity Group increased their target price on shares of Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Barclays upped their price objective on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. TD Cowen lifted their target price on shares of Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. BTIG Research boosted their target price on shares of Guardant Health from $100.00 to $140.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, Leerink Partners upped their price target on shares of Guardant Health from $115.00 to $155.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Twenty-two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $102.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Baillie Gifford & Co. increased its stake in Guardant Health by 6.6% in the third quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock valued at $320,378,000 after purchasing an additional 317,906 shares in the last quarter. Invesco Ltd. grew its stake in shares of Guardant Health by 27.3% in the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock valued at $185,184,000 after buying an additional 763,834 shares during the period. Franklin Resources Inc. increased its position in Guardant Health by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after buying an additional 606,368 shares in the last quarter. Geode Capital Management LLC increased its position in Guardant Health by 0.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,920,714 shares of the company’s stock valued at $152,014,000 after buying an additional 13,088 shares in the last quarter. Finally, ARK Investment Management LLC raised its stake in Guardant Health by 100.4% during the 2nd quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock worth $146,935,000 after buying an additional 1,414,381 shares during the period. 92.60% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.